Vaccination against hepatitis A is an important intervention to prevent disease in HIV-
patients. There are insufficient data on the association of the response to hepatitis A vaccine …

HIV-infected patients are at increased risk for acquiring hepatitis A virus (HAV) infection. We
evaluated the seroconversion rate (anti-HAV antibodies≥ 20 mIU/ml) and the geometric …

Objectives The aim of this study was to evaluate the impact of various factors that may
influence the immunologic response to hepatitis A mono-vaccine or hepatitis A/B co-vaccine …

The aim of this study was to estimate the prevalence of total antibodies to hepatitis A virus
(anti-HAV-T) in the group of HIV-positive adults in Lodz region of Poland, and to evaluate the …

Introduction HIV seropositivity is considered a risk factor for complications in hepatitis A virus
(HAV) infection. HAV vaccination schedules are widely implemented in HIV-infected …

The USPHS/IDSA guidelines for Prevention of Opportunistic Infections in Persons with
human immunodeficiency virus (HIV) recommends that all susceptible HIV+ patients at …

Background: The immunogenicity of vaccines, including vaccine against hepatitis A virus
(HAV), is impaired in patients with HIV infection, requiring revised immunization regimens …

Background. Hepatitis A is a major health risk for many human immunodeficiency virus (HIV)-
infected individuals. Vaccination is a potentially attractive measure to reduce the incidence …

Background. Vaccination provides long-term immunity to hepatitis A virus (HAV) among the
general population, but there are no such data regarding vaccine durability among human …

Hepatitis A virus (HAV) infection remains a health risk for human immunodeficiency virus
(HIV)‐infected persons. While the inactivated HAV vaccine affords protection to …